EGEIRO's Board of Directors Acknowledges the Resignation of Enrico Bastianelli and Modifies Its Governance
18 Novembro 2024 - 2:00PM
Business Wire
Regulatory News:
EGEIRO Pharma (ISIN : BE0974387194 - mnemo : ALVET), a
biopharmaceutical company specializing in the repositioning and
reformulation of existing drugs, notably in Idiopathic Pulmonary
Fibrosis, announces that its Board of Directors meeting on November
15, 2024 has acknowledged the resignation of Enrico Bastianelli as
a Director and has decided to modify its governance. Gaëtan
Terrasse has been appointed Managing Director and Emmanuel Huynh
Chairman. Catherine Bur remains a director.
About EGEIRO Pharma
EGEIRO Pharma is a biopharmaceutical company specializing in the
repositioning and reformulation of existing drugs to deliver
impactful improvements for patients and meet the new needs of
healthcare professionals and organizations. The company's strategy
is currently focused on the clinical development of an innovative
drug for Idiopathic Pulmonary Fibrosis, a chronic, devastating and
fatal disease characterized by the progressive deterioration of
lung function.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241118817308/en/
EGEIRO Pharma contact@egeiro.be
EGEIRO Pharma (EU:ALVET)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
EGEIRO Pharma (EU:ALVET)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
